NCT02581085View on ClinicalTrials.gov

Tocotrienol Against the Progression of End Stage Liver Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
End Stage Liver DiseaseNASH - Nonalcoholic SteatohepatitisNAFLD - Nonalcoholic Fatty Liver Disease
Interventions
DRUG

Tocotrienol (TCT)

TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.

OTHER

Placebo

Control study capsule that includes no study product (Vitamin E - Tocotrienol)

Trial Locations (1)

46202

IU Health Unviersity Hospital, Indianapolis

All Listed Sponsors
collaborator

Malaysia Palm Oil Board

OTHER_GOV

collaborator

Indiana University

OTHER

lead

Chandan Sen

OTHER

NCT02581085 - Tocotrienol Against the Progression of End Stage Liver Disease | Biotech Hunter | Biotech Hunter